Table 3.
Comparison of vaccine adverse events between type 1 diabetes and healthy controls of the matched cohort: results from propensity score matching analysis
| Type 1 diabetes patients (n = 72) | HCs (n = 280) | OR (95% CI) | P‐value | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Any AE | 54 (75.0) | 203 (72.5) | – | 0.670 |
| Injection site pain | 37 (51.4) | 139 (49.6) | – | 0.792 |
| Minor adverse reaction to vaccine | ||||
| Any minor AE | 54 (75.0) | 203 (72.5) | – | 0.670 |
| Myalgia | 9 (12.5) | 37 (80.4) | – | 0.873 |
| Body ache | 12 (16.7) | 40 (14.3) | – | 0.612 |
| Fever | 17 (23.6) | 36 (12.9) | 2.0 (1.1–4.0) | 0.023 |
| Chills | 8 (11.1) | 20 (7.1) | – | 0.267 |
| Nausea and vomiting | 5 (6.9) | 9 (3.2) | – | 0.149 |
| Headache | 13 (18.1) | 51 (18.2) | – | 0.975 |
| Rashes | 1 (1.4) | 3 (1.1) | – | 0.821 |
| Fatigue | 17 (23.6) | 63 (22.5) | – | 0.841 |
| Diarrhea | 4 (5.6) | 3 (1.1) | 5.4 (1.1–24.8) | 0.015 |
| Abdominal pain | 1 (1.4) | 2 (0.7) | – | 0.579 |
| Rise in blood pressure | 0 (0) | 1 (0.4) | – | 0.612 |
| Difficulty in breathing | 1 (1.4) | 2 (0.7) | – | 0.579 |
| Dizziness | 6 (8.3) | 7 (2.5) | 3.5 (1.1–10.9) | 0.019 |
| Chest pain | 1 (1.4) | 3 (1.1) | – | 0.821 |
| Others | 2 (2.7) | 19 (6.7) | – | 0.299 |
| Major AEs | ||||
| Any major AEs | 2 (2.8) | 7 (2.5) | – | 0.894 |
| Anaphylaxis | 0 (0) | 0 (0) | – | – |
| Marked difficulty in breathing | 1 (1.4) | 3 (1.1) | – | 0.821 |
| Throat closure | 0 (0) | 0 (0) | – | – |
| Severe rashes | 2 (4) | 2 (0.7) | – | 0.141 |
| Others | 0 (0) | 0 (0) | – | – |
| Hospitalization | 1 (1.4) | 1 (0.4) | – | 0.299 |
AE, adverse effect; CI, confidence interval; HC, healthy control; OR, odds ratio.